BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
Acalabrutinib
BTK inhibitors
Frontline therapy
Ibrutinib
Tirabrutinib
Untreated
Waldenström macroglobulinemia
Zanubrutinib
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
medline:
3
7
2023
pubmed:
29
5
2023
entrez:
28
5
2023
Statut:
ppublish
Résumé
The discovery of MYD88 (L265P) mutation led to investigating BTK inhibitors in Waldenström macroglobulinemia (WM). Ibrutinib, the first-in-class agent, was approved based on a phase II trial in relapsed/refractory patients. In the phase III iNNOVATE study, the combination of rituximab and ibrutinib was compared with rituximab and placebo in treatment-naïve and relapsed/refractory patients. Second-generation BTK inhibitor, zanubrutinib, was compared with Ibrutinib in MYD88-mutated WM patients in the phase III ASPEN trial, whereas acalabrutinib was investigated in a phase II trial. Here, we discuss the role of BTK inhibitors in treatment-naïve patients with WM based on currently available evidence.
Identifiants
pubmed: 37246088
pii: S0889-8588(23)00039-4
doi: 10.1016/j.hoc.2023.04.005
pii:
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Myeloid Differentiation Factor 88
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
707-717Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.